Pharmaceutical industry in pediatric drug development: partners and collaborators with academia and the FDA

Journal of Pediatric Gastroenterology and Nutrition

Volumn 47, Issue 5, 2008, Pages 711-713

  Mulberg, Andrew E ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN 1A AGONIST; SEROTONIN 3 AGONIST; SEROTONIN 4 AGONIST; SEROTONIN 4 ANTAGONIST;

CANADA; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CONFERENCE PAPER; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG METABOLISM; ENTERITIS; ENTEROPATHY; EUROPE; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HEALTH CARE; HEPATITIS B; HEPATITIS C; HUMAN; HYPERCHOLESTEROLEMIA; INTERNATIONAL COOPERATION; IRRITABLE COLON; LAW; METABOLIC REGULATION; PATHOLOGY; PEDIATRICS; PHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STOMACH EMPTYING; VOMITING; ARTICLE; CHILD; UNITED STATES;

CHILD; DRUG INDUSTRY; HUMANS; IRRITABLE BOWEL SYNDROME; PEDIATRICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 59849117674     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpg.0000338970.57088.89     Document Type: Conference Paper

References (3)

1. Shirkey H. Editorial comment: therapeutic orphans. J Pediatr 1968;72:119-20.
2. US Food and Drug Administration. Office of Pediatric Therapeutics. http://www.fda.gov/oc/opt/default.htm. Accessed September 2007.
3. USFood and Drug Administration.FDA'scritical pathinitiative. http:// www.fda.gov/oc/initiatives/criticalpath. Accessed September 2007.